LXRXNasdaqPharmaceutical PreparationsFiscal year ends December 31

LEXICON PHARMACEUTICALS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$1.55+0.03 (+1.97%)

Close on Oct 19, 2026

Market cap: $678.36M
P/E (TTM): –
Dividend yield: –

LEXICON PHARMACEUTICALS, INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Revenue	50	31	1.20	0.14	0.30	24	322	63	92	79	130	23	2.22	1.09	1.85	4.91	11
Cost of Revenue	0.27	0.62	0.09	0	0	1.93	3.23	2.49	1.90	0	0	–	–	–	–	–	–
Gross Profit	50	30	1.12	0.14	0.30	22	319	61	90	79	130	–	–	–	–	–	–
Research & Development	61	84	59	53	55	154	92	100	152	164	95	89	90	83	92	79	81
Selling, General & Admin	37	143	114	48	32	–	–	–	–	–	–	–	–	–	–	–	–
General & Administrative	–	–	–	48	32	47	57	64	66	43	24	19	17	17	17	19	19
Operating Expenses	–	–	–	101	87	204	181	166	222	206	129	123	105	110	116	101	101
Total Costs & Expenses	99	228	173	101	87	–	–	–	–	–	–	–	–	–	–	–	–
Operating Income	-49	-197	-172	-101	-87	-48	141	-103	-131	-127	1.47	-100	-102	-108	-114	-96	-90
Interest Expense	–	–	–	2.78	0.80	15	21	21	6.98	6.57	6.72	2.25	1.97	2.11	2.53	2.72	2.97
Interest & Investment Income	–	–	–	–	–	–	–	–	–	–	–	–	0.16	0.21	0.26	0.52	0.88
Other Non-Operating Income	6.91	12	7.73	1.60	0.13	2.77	3.35	3.51	1.95	2.29	0.57	2.26	0.22	0.32	0.15	-4.02	-2.55
Merger & Restructuring Charges	–	–	–	–	–	–	–	–	–	–	–	5.70	–	–	–	–	–
Asset Impairment Charges	0	0	0	0	0	1.60	29	0	0	0	3.60	13	0	0	0.70	1.00	0.44
Gain (Loss) on Investments	–	–	–	–	–	–	–	–	–	–	–	–	–	0	0	0.14	1.17
Gain (Loss) on Sale of Assets	–	0	0	0.00	-0.05	0.71	0	0	0.00	-0.02	0.05	1.63	0	0	–	–	–
Pretax Income	–	–	–	–	-88	-59	124	-121	-136	-131	-4.68	-100	-104	-110	-116	-102	-93
Income Tax Expense	–	0	0	0	0	–	–	–	–	0	0	-0.07	0	0	0	-0.03	-0.10
Net Income incl. Noncontrolling Interests	–	–	–	-102	-88	-59	130	-121	-123	-131	-4.68	-100	-104	-110	-116	-102	-93
Minority Interest in Earnings	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0	0	-11
Net Income	-50	-200	-177	-102	-88	-59	130	-121	-123	-131	-4.68	-100	-104	-110	-116	-102	-83
EPS (Basic)(per share)	-0.14	-0.63	-0.80	-0.62	-0.60	-0.53	1.23	-1.14	-1.17	-1.27	-0.05	-1.31	-1.42	-1.61	-2.38	-2.38	-3.99
EPS (Diluted)(per share)	-0.14	-0.63	-0.80	-0.62	-0.60	-0.53	1.16	-1.14	-1.17	-1.27	-0.05	-1.31	-1.42	-1.61	-2.38	-2.38	-3.99
Shares Outstanding (Basic, Weighted)(shares)	363	320	221	166	146	–	–	106	105	104	104	76	73	70	49	43	–
Shares Outstanding (Diluted, Weighted)(shares)	363	320	221	166	146	111	117	106	105	104	104	76	73	70	49	43	–
EBITDA	-48	-197	-171	-100	-87	-45	145	-100	-127	-125	2.20	-98	-100	-104	-109	-90	-84

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 99.1%
Operating margin: -131.4%
Net margin: -147.4%
Return on equity, FY2025: -39.7%

Financial strength

Current ratio: 13.37
Debt to equity: 0.29
Debt to assets: 20.6%
Cash to current liabilities: 278.3%

Valuation

P/E ratio: –
Price to sales: 16.36
Price to book: 3.89
Dividend yield: –